Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis
NCT00432900 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21
Last updated 2019-12-12
Summary
This study will use positron emission tomography (PET) to measure a brain protein called peripheral benzodiazepine receptor (PBR) in patients with multiple sclerosis. PBR is created during the inflammation process, and brain inflammation is a key feature of multiple sclerosis (MS). PBR usually affects one type of brain cell, but it can also cause damage to surrounding areas of the brain in patients with MS. PET studies of PBRs and brain inflammation may help elucidate the role of these brain cells in patients with MS.
Healthy normal volunteers and patients with MS between 18 and 70 years of age may be eligible for this study. Patients with MS must have had onset of disease between 18 and 40 years of age.
Patients with MS undergo the following procedures:
Visit 1: Medical history, physical examination, blood tests and magnetic resonance imaging (MRI).
Visit 2: Blood tests and PET scan.
Visits 3 and 4: MRI and physical examination.
Visit 5: PET scan and blood tests.
Visit 6: MRI and physical examination.
Healthy volunteers undergo the following:
Visit 1: Medical history, physical examination, blood tests.
Visits 2 and 3: PET and blood tests.
Magnetic Resonance Imaging
MRI uses a magnetic field and radio waves to produce images of body tissues and organs. For this procedure, the subject lies on a table that can slide in and out of the scanner (a metal cylinder), wearing earplugs to muffle loud knocking noises that occur during the scanning process. The procedure lasts about 90 minutes; the patient is asked to lie still for up to 25 minutes at a time. The subject can communicate with the MRI staff at all times during the scan. During part of the scan a contrast agent is administered through a catheter (plastic tube) placed in an arm vein to enhance the images.
Positron Emission Tomography (PET)
The PET scan gives information on brain and body chemistry and function. The subject lies on a bed that slides in and out of the doughnut-shaped scanner. A catheter is placed in a vein in the arm and another is placed in an artery in the wrist or elbow area. The catheter in the arm is used for injecting a radioactive material that the scanner detects, and the other is used to collect blood samples. A custom-molded plastic mask is used to support the head and prevent it from moving during the procedure. The subject may be asked to perform various tasks during the PET scan or to lie quietly. The scan lasts about 2.5 hours.
Conditions
Interventions
- RADIATION
-
[(11)C]PBR28
PET Ligand
Sponsors & Collaborators
-
National Institute of Neurological Disorders and Stroke (NINDS)
lead NIH
Principal Investigators
-
Steven Jacobson, Ph.D. · National Institute of Neurological Disorders and Stroke (NINDS)
Study Design
- Allocation
- NA
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2007-02-05
- Primary Completion
- 2013-05-23
- Completion
- 2013-05-29
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
NCT01028209 ·Status: TERMINATED ·Phase: PHASE1
-
PET Imaging of Peripheral Benzodiazepine Receptors
NCT00696371 ·Status: COMPLETED
-
Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA
NCT03033680 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28
NCT00526916 ·Status: COMPLETED ·Phase: PHASE1
-
PET Whole Body Imaging Using a Peripheral Benzodiazepine Receptor Ligand [C-11]PBR28
NCT00407693 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET
NCT03876002 ·Status: COMPLETED ·Phase: PHASE1
-
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Carotid Atherosclerosis
NCT00547976 ·Status: COMPLETED ·Phase: PHASE1
-
PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)
NCT00459693 ·Status: TERMINATED ·Phase: NA
-
Translocator Protein and Inflammation After Traumatic Brain Injury
NCT01547780 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
TSPO-PET/MRI in Surveillance of Neuroinflammation in the Central Nervous System
NCT06467773 ·Status: RECRUITING
-
Correlation Between PET and Advanced MRI in Multiple Sclerosis
NCT02869360 ·Status: COMPLETED
-
Metabolic Imaging of Neurological Disease
NCT06900244 ·Status: ENROLLING_BY_INVITATION
-
Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)
NCT06289582 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
NCT02836327 ·Status: UNKNOWN
-
Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
NCT01209156 ·Status: COMPLETED ·Phase: PHASE1
-
Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis
NCT00393588 ·Status: COMPLETED
-
PET with [18F]Flumazenil As an Index of Neurodegeneration in MS
NCT03825601 ·Status: COMPLETED ·Phase: NA
-
Reproducibility of the 11C-PBR28 PET Signal
NCT02086240 ·Status: WITHDRAWN ·Phase: NA
-
Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis
NCT00321568 ·Status: COMPLETED
-
Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis
NCT00099307 ·Status: COMPLETED
-
Prognosis Value of the Neuronal Damage in Early Multiple Sclerosis
NCT01651520 ·Status: UNKNOWN ·Phase: NA
-
Positron Emission Tomography (PET) to Study Brain Signaling
NCT00044200 ·Status: COMPLETED
-
Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions
NCT00970333 ·Status: COMPLETED ·Phase: PHASE1
-
PET Study of the Nicotinic System in Epilepsy
NCT03268369 ·Status: COMPLETED ·Phase: NA
-
Microglial Cells Activation Imaging Using PET-CT With 18F-DPA714
NCT04171882 ·Status: UNKNOWN